Related Experiment Video
Updated: Jul 5, 2026
06:33
Optimized Protocol for Generating Functional Pancreatic Insulin-secreting Cells from Human Pluripotent Stem Cells
Published on: February 2, 2024
The insulin-like growth factor system: towards clinical applications
1University of Melbourne, Department of Medicine (Austin Health/Northern Health) Austin Hospital, Heidelberg, VIC, Australia. l.bach@unimelb.edu.au
The Clinical Biochemist. Reviews
|May 7, 2008
Summary
Insulin-like growth factors (IGF) regulate growth and are implicated in diseases like cancer and diabetes. Understanding the complex IGF system is crucial for developing targeted therapies and improving disease diagnosis.
Area of Science:
- Endocrinology
- Molecular Biology
- Physiology
Background:
- Insulin-like growth factors (IGF-I and II) are key regulators of growth, acting via endocrine, paracrine, and autocrine pathways.
- IGFs mediate cellular proliferation, survival, and differentiation, primarily through the IGF-I receptor, but also interact with other receptors.
- IGF activity is modulated by IGF binding proteins (IGFBPs), which can inhibit or enhance IGF actions.
Purpose of the Study:
- To review the multifaceted roles of the IGF system in physiological growth and disease.
- To highlight the diagnostic utility of IGF and IGFBP assays.
- To discuss the therapeutic potential and challenges associated with targeting the IGF system.
Main Methods:
- Review of existing literature on IGF biology, disease associations, and therapeutic interventions.
- Analysis of the roles of IGF-I, IGF-II, and IGFBPs in various physiological and pathological conditions.
- Examination of current and emerging diagnostic and therapeutic strategies involving the IGF system.
Main Results:
- Alterations in the IGF system are linked to diabetes, cancer, cardiovascular, and neuromuscular diseases.
- Epidemiological studies associate high IGF-I with certain cancers and low IGF-I with ischemic heart disease.
- IGF-I and IGFBP-3 assays show utility in managing acromegaly and growth hormone deficiency.
Conclusions:
- The IGF system plays a critical role in human health and disease, necessitating a deeper understanding for targeted interventions.
- Development of specific therapeutics targeting the IGF system is essential, given the complex and sometimes opposing roles observed.
- Increased availability of IGF and IGFBP assays will likely enhance their diagnostic and monitoring capabilities for various diseases.
Related Concept Videos
01:28Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...